Drug updated on 4/17/2024
| Dosage Form | Solution (topical; 0.02%) |
| Drug Class | Rho kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Summary
- Netarsudil (Rhopressa) is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
- Two systematic reviews/meta-analyses were reviewed, providing insights into the efficacy and safety of netarsudil compared to other treatments for these conditions.
- The first review found that netarsudil may be slightly less effective than timolol and latanoprost in reducing intraocular pressure, but when combined with latanoprost it likely results in further reductions compared to monotherapy.
- However, both as a single treatment and in combination therapy with latanoprost, netarsudil was associated with more ocular adverse events; although these were generally described as mild and reversible upon discontinuation of treatment.
- The second meta-analysis confirmed that fixed-dose combination therapy using netarsudil/latanoprost significantly reduces intraocular pressure more effectively than latanoprost alone after 2 weeks up to 6 weeks of administration.
- This study also reported an increased risk of conjunctival hyperemia (CH) - redness or inflammation caused by dilated blood vessels near the surface - among patients receiving either this combination therapy or just netarsudil compared to those on only latanoprost; however most CH symptoms were mild and few patients discontinued medication due to them during clinical trials examined here.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Rhopressa (netarsudil) Prescribing Information. | 2019 | Aerie Pharmaceuticals, Inc., Irvine, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension. | 2022 | Cochrane Database of Systematic Reviews |
| Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis. | 2022 | Korean Journal of Opthalmology |